Genprex, Inc. short interest in 2021
In 2021, Genprex, Inc.'s disclosed short interest ran from 10.21% of shares outstanding on 15 Jan 2021 to 4.39% on 31 Dec 2021, a change of -5.82 percentage points. The year's high was 10.57% on 29 Jan 2021 and its low 4.39% on 31 Dec 2021, averaging 7.00% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.21 days on 28 May 2021. Full history: Genprex, Inc..
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2021 in figures
- Start of year
- 10.21% (15 Jan 2021)
- End of year
- 4.39% (31 Dec 2021)
- Change
- -5.82 pp
- High
- 10.57% (29 Jan 2021)
- Low
- 4.39% (31 Dec 2021)
- Average
- 7.00%
- Highest days to cover
- 10.21 (28 May 2021)
- SEC filings marked
- 4
Every report in 2021
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2021 | 10.21% | 3.19 | |
| 29 Jan 2021 | 10.57% | 2.62 | |
| 12 Feb 2021 | 8.25% | 1.13 | |
| 26 Feb 2021 | 8.04% | 3.11 | |
| 15 Mar 2021 | 8.07% | 3.30 | |
| 31 Mar 2021 | 10.04% | 4.78 | 10-K filed |
| 15 Apr 2021 | 9.64% | 4.25 | |
| 30 Apr 2021 | 9.62% | 6.13 | |
| 14 May 2021 | 9.51% | 5.06 | |
| 28 May 2021 | 9.23% | 10.21 | 10-Q filed |
| 15 Jun 2021 | 8.58% | 6.82 | |
| 30 Jun 2021 | 6.45% | 2.85 | |
| 15 Jul 2021 | 6.45% | 5.45 | |
| 30 Jul 2021 | 6.02% | 5.88 | |
| 13 Aug 2021 | 4.95% | 5.29 | 10-Q filed |
| 31 Aug 2021 | 4.82% | 4.71 | |
| 15 Sep 2021 | 4.95% | 7.35 | |
| 30 Sep 2021 | 4.83% | 8.22 | |
| 15 Oct 2021 | 4.70% | 9.23 | |
| 29 Oct 2021 | 4.82% | 4.01 | |
| 15 Nov 2021 | 4.76% | 7.58 | 10-Q filed |
| 30 Nov 2021 | 4.62% | 3.06 | |
| 15 Dec 2021 | 4.56% | 4.79 | |
| 31 Dec 2021 | 4.39% | 4.25 |
See also: Genprex, Inc.'s full history · most shorted US stocks of 2021 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.